Three quarters of a mile from civilization

Views, analysis & commentary - essentially on venture capital & pharmaceutical industry

Showing posts with label Attrition. Show all posts
Showing posts with label Attrition. Show all posts
Thursday, January 24, 2013

The clinical attrition of INX-189 post a 2.5 billion acquisition - are investors into life sciences really looking at where the buck is headed?

›
October 2012 Discussion initiated on Global Private Equity & Venture Capital  group on Linkedin http://www.linkedin.com/groupItem?vi...
1 comment:

INX-189 clinical attrition - a call for re-look at single isomer strategy of Gilead?

›
October 2012 Discussion posted Pharmaceutical Discussion Group on LinkedIn http://www.linkedin.com/groups/INX-189-clinical-attrition...
›
Home
View web version
Powered by Blogger.